Book excerpt: The often-confrontational debate over the development of agricultural and pharmaceutical products made with the help of genetic modification has drastically limited the exploitation of this still new technology. This book focuses on the risk and rewards of genetic modification, the differing paths the dialogue on GM has followed in Europe and the developing world in contrast to the United States, how the debate impacts the commercial realities of companies developing new products, and what strategies might foster more constructive discussion over the costs and benefits of genetic manipulation to bring about more rational and internationally coordinated public policy.